Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro

Novo Nordisk OMXCOP:NOVO_B said on Tuesday a real-world study found that adults with type 2 diabetes who took an escalated dose of its diabetes drug, Ozempic, had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's NYSE:LLY Mounjaro.The company said patients wh…